Ibrance (Palbociclib) Capsules
Trade name: Ibrance.
Ibrance is manufactured by Pfizer Inc.
Ibrance FDA Approval:
Ibrance first approved February 3rd, 2015.
Ibrance Dosage form:
Capsules: 75mg, 100mg, 125mg.
Ibrance Indications and Usage:
- Treatment of postmenopausal women with estrogen receptor (ER)-positive.
- Human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based treatment for metastatic disease.
Ibrance (Palbociclib) Capsules availability in India
- You could import this medicine against import permit on Patient Name.
- Please contact ACT Lifesciences Private Limited for further information.